August 1, 2007 - Positron Corp. announced that a recent study by The State University of New York at Buffalo reveals that Positron Emission Tomography (PET) scanning when used as the first tool to diagnose heart-vessel blockages, is more accurate, less invasive and cost effective than SPECT imaging. The research findings, published in the July edition of the Journal of Nuclear Medicine, support PET scanning as the initial diagnostic test for assessing a patient's risk of heart attack, according to lead researcher Michael Merhige, M.D., UB clinical associate professor of nuclear medicine and Director of the Heart Center of Niagara at Niagara Falls Memorial Medical Center. "Because PET scanning is more accurate and provides a clearer picture of the state of the heart than conventional SPECT imaging, we found a decrease in the use of angiograms and bypass surgery by more than 50 percent if used as the first-line test with patients when all too often it is the last test," indicated Dr. Merhige. The study also says that invasive procedures such as coronary arteriography, coronary bypass surgery and stent implantation are over utilized in the U.S., as false readings from SPECT require unnecessary angiograms, for example, that turn out to be normal. PET, however, does not produce as many false positives or false negatives because the images have higher resolution and better contrast, noted Dr. Merhige. For more information: www.positron.com
If you enjoy this content, please share it with a colleague
Related Content
May 8, 2024 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of ...
May 1, 2024 — Sun Nuclear, a Mirion Medical company, today announced the upcoming version 5.0 release of its SunCHECK ...
April 10, 2024 — Blue Earth Therapeutics, a Bracco company and emerging leader in the development of innovative next ...
April 5, 2024 — RLS Radiopharmacies, America’s only Joint Commission-accredited radiopharmacy network, today announced ...
March 29, 2024 — Magnetic resonance imaging (MRI) is a cornerstone in the landscape of medical diagnostics, celebrated ...
February 21, 2024 — Blue Earth Therapeutics, a Bracco company and emerging leader in the development of innovative next ...
February 14, 2024 — PanTera, the Belgian joint venture created by IBA and SCK CEN to secure large-scale production of ...
February 12, 2024 — IBA, a world leader in particle accelerator technology and a world-leading provider of dosimetry and ...
February 9, 2024 — A novel PET imaging technique can noninvasively detect active inflammation in the body before ...
February 6, 2024 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI) held its 2024 SNMMI Mid-Winter Meeting ...